Somatostatin (SST), a neuropeptide expressed in dendritic-targeting gamma-aminobutyric acid (GABA) neurons, is decreased across corticolimbic areas in major depressive disorder (MDD). SST-positive GABA neurons form heterogeneous subgroups with different laminar distributions and electrophysiological properties, so knowing the anatomical and cellular localization of reduced SST may provide insight into the nature of the pathology in MDD. In cohorts of MDD subjects with known reduction of SST in postmortem sgACC gray matter, we used in situ hybridization to quantify the laminar and cellular patterns of altered SST mRNA expression. SST mRNA levels were lower across all cortical layers in the MDD subjects. Expression levels per cell were also lower, but the density of labeled neurons did not differ between subject groups. Consistent with the previous tissue level analysis, differences were more robust in females. In summary, we report MDD-related reduction in SST expression per cell across cortical layers in sgACC, suggesting a general vulnerability of SST neurons independent of specific cell type.
Introduction
Somatostatin (SST), a neuromodulatory peptide, is expressed in a subtype of GABA neurons that inhibits the dendritic compartment of principal excitatory glutamatergic neurons (Viollet et al., 2008) . Lower SST expression has been reported in psychiatric and neurodegenerative disorders, including schizophrenia (Morris et al., 2008) , bipolar disorder (Konradi et al., 2011 ) and Alzheimer's disease (Gahete et al., 2010) . In major depressive disorder (MDD), we reported a downregulation of SST mRNA expression in the dorsolateral prefrontal cortex (Sibille et al., 2011) , subgenual anterior cingulate cortex (sgACC) (Tripp et al., 2011 (Tripp et al., , 2012 and in the lateral and basomedial nuclei of the amygdala (Guilloux et al., 2012) compared to that in control subjects. Differences were more robust in female MDD subjects in sgACC and were restricted to women with MDD in the amygdala (Guilloux et al., 2012; Sibille et al., 2009) . These findings were consistent with postmortem studies showing reduced calbindin-positive GABA neuron density in MDD (Maciag et al., 2010; Rajkowska et al., 2007) , as SST is largely co-localized with calbindin [reviewed in (Viollet et al., 2008) ].
SST cells represent~18-20% of interneurons across cortical regions, but are not evenly distributed across cortical layers (Lewis et al., 1986; McDonald and Mascagni, 2002; Weckbecker et al., 2003) . At least three different subtypes of SST neurons have been identified through the generation of transgenic mice expressing green fluorescent protein (GFP) in SST cells (Ma et al., 2006; Oliva et al., 2000) . So-called GIN and X98 mice express GFP in layers 2/3 and 5 SST neurons, and send abundant projections to layer 1. These neurons include the traditional low threshold spiking Martinotti cells that provide inhibitory inputs to the distal dendrites of pyramidal neurons. In contrast, GFP-expressing cells in X94 mice represent a population of SST neurons in layer 4 (or deep layer 3 in agranular sgACC), which do not project to layer 1, display "stuttering" electrophysiological properties, and target layer 4 parvalbumin-positive GABA neurons (Xu et al., 2013) . Consistent with these differences in innervation patterns, optogenetic-induced activity of layer 2/3/5 SST neurons resulted in pyramidal cell inhibition, while activity of layer 4 (or deep layer 3 in agranular sgACC) resulted in pyramidal cell disinhibition (Xu et al., 2013) . Accordingly, in MDD, a reduction in SST function in agranular layer 3 of the sgACC might result in decreased excitation of pyramidal cells. On the other hand, reduction in SST function in layers 2/3/5 might result in increased excitation of pyramidal cells.
Accordingly, understanding whether all or a specific subset of SST cells are affected in MDD has important implications for understanding the nature of the circuit dysfunction. Here, we tested two alternative hypotheses regarding the role of SST reduction in MDD. First, SST Neurobiology of Disease 73 (2015) 213-219 
